B-Vaxx / Imugene - LARVOL DELTA

HER-2 B Cell Peptide Vaccine (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Pravin T.P Kaumaya | Trial completion date: Jun 2027 ➔ Dec 2030 | Trial primary completion date: Dec 2026 ➔ Dec 2029

Trial completion date • Trial primary completion date • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Pravin T.P Kaumaya | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Pravin T.P Kaumaya | Initiation date: Jun 2024 ➔ Sep 2024

Metastases • Trial initiation date • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Pravin T.P Kaumaya

Metastases • New P1 trial • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Robert Wesolowski | Recruiting ➔ Completed | N=100 ➔ 65 | Trial completion date: Dec 2023 ➔ Nov 2022 | Trial primary completion date: Dec 2023 ➔ Nov 2022

Enrollment change • IO biomarker • Metastases • Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Colon Cancer • Colorectal Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • EGFR • HER-2

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Pravin Kaumaya | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

IO biomarker • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Colon Cancer • Colorectal Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • EGFR • HER-2

A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). (PubMed, Oncoimmunology) - "The combination of HER-2 vaccine (B-Vaxx) with either PDL1-Vaxx or PD1-Vaxx demonstrated synergistic tumor inhibition. PDL1-Vaxx is a promising novel safe checkpoint inhibitor vaccine."

Combination therapy • Journal • Preclinical • Infectious Disease • Oncology • Tetanus • HER-2 • PD-L1

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=100; Recruiting; Sponsor: Pravin Kaumaya; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Dec 2022

Clinical • IO biomarker • Trial completion date • Trial primary completion date • Breast Cancer • Colon Cancer • Colorectal Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • EGFR • HER-2